Frederic Commo
Overview
Explore the profile of Frederic Commo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
1790
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garrido M, Martin N, Bertrand M, Gaudin C, Commo F, El Kalaany N, et al.
Clin Cancer Res
. 2018 Oct;
25(2):710-723.
PMID: 30322877
Purpose: Targeted therapies that use the signaling pathways involved in prostate cancer are required to overcome chemoresistance and improve treatment outcomes for men. Molecular chaperones play a key role in...
2.
Pailler E, Oulhen M, Borget I, Remon J, Ross K, Auger N, et al.
Cancer Res
. 2017 May;
77(9):2222-2230.
PMID: 28461563
The duration and magnitude of clinical response are unpredictable in -rearranged non-small cell lung cancer (NSCLC) patients treated with crizotinib, although all patients invariably develop resistance. Here, we evaluated whether...
3.
Lefebvre C, Bachelot T, Filleron T, Pedrero M, Campone M, Soria J, et al.
PLoS Med
. 2016 Dec;
13(12):e1002201.
PMID: 28027327
Background: Major advances have been achieved in the characterization of early breast cancer (eBC) genomic profiles. Metastatic breast cancer (mBC) is associated with poor outcomes, yet limited information is available...
4.
Commo F, Guinney J, Ferte C, Bot B, Lefebvre C, Soria J, et al.
Bioinformatics
. 2015 Dec;
32(9):1402-4.
PMID: 26708336
Unlabelled: We present rCGH, a comprehensive array-based comparative genomic hybridization analysis workflow, integrating computational improvements and functionalities specifically designed for precision medicine. rCGH supports the major microarray platforms, ensures a...
5.
Semeraro M, Rusakiewicz S, Minard-Colin V, Delahaye N, Enot D, Vely F, et al.
Sci Transl Med
. 2015 Apr;
7(283):283ra55.
PMID: 25877893
The immunosurveillance mechanisms governing high-risk neuroblastoma (HR-NB), a major pediatric malignancy, have been elusive. We identify a potential role for natural killer (NK) cells, in particular the interaction between the...
6.
Albiges L, Goubar A, Scott V, Vicier C, Lefebvre C, Alsafadi S, et al.
Breast
. 2014 Mar;
23(3):250-8.
PMID: 24636978
Objectives: Bioinformatics analyses of pathways and genes differentially expressed between malignant and benign lesions could allow discovering new therapeutic targets. Here, we identified Checkpoint kinase 1 (Chk1) as a potent...
7.
Al Nakouzi N, Cotteret S, Commo F, Gaudin C, Rajpar S, Dessen P, et al.
Oncotarget
. 2014 Feb;
5(3):667-78.
PMID: 24525428
Docetaxel is used as a standard treatment in patients with metastatic castration-resistant prostate cancer. However, a large subset of patients develops resistance. Understanding resistance mechanisms, which are largely unknown, will...
8.
Andre F, Bachelot T, Commo F, Campone M, Arnedos M, Dieras V, et al.
Lancet Oncol
. 2014 Feb;
15(3):267-74.
PMID: 24508104
Background: Breast cancer is characterised by genomic alterations. We did a multicentre molecular screening study to identify abnormalities in individual patients with the aim of providing targeted therapy matched to...
9.
Broutin S, Commo F, De Koning L, Marty-Prouvost B, Lacroix L, Talbot M, et al.
Thyroid
. 2013 Nov;
24(1):43-51.
PMID: 24256343
Background: Medullary thyroid carcinoma (MTC) is a rare tumor that is caused by activating mutations in the proto-oncogene RET. Vandetanib, a tyrosine-kinase inhibitor, has been recently approved to treat adult...
10.
Cortot A, Younes M, Martel-Planche G, Guibert B, Isaac S, Souquet P, et al.
Clin Lung Cancer
. 2013 Oct;
15(2):124-30.
PMID: 24169260
Background: In lung adenocarcinoma, inactivation of the tumor suppressor p53 may abrogate a safeguard mechanism preventing the development of tumors with activating mutations in EGFR or KRAS. To assess this...